TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Related to this article
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
Advertisement
Advertisement
Trending on OncLive
1
Roswell Park Researchers Identify Strategy for Overcoming Resistance to RAS-Targeted Cancer Drugs
2
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma
3
How Biomarkers Now Drive First-Line Therapy in mHSPC
4
Coordinating the Timing of Interventions in NETs
5